The European Patent Office (EPO) has as expected decided to grant Lifecare a new patent for an updated sensor measuring system. The now approved patent expands Lifecare’s protection in time and scope.
As announced in Lifecare’s press release 25.03.21, the EPO by then intended to grant this patent, about an “interstitial fluid osmotic pressure measuring device system and method”. This protection is now confirmed and ensured until 2038. The new patent represents a fundamental addition to Lifecare’s IP and an important next step utilizing the Sencell technology from research and development to a broader commercialization. The sensor design described in the new patent intends to improve signal amplitude, increase the accuracy of subcutaneous glucose assessment, and to improve sensor longevity and robustness against environmental interferences. This new sensor version is also suitable for measurement of other analytes, in addition to glucose.
“As mentioned in March, this European patent will strengthen our position for correct and continuous monitoring of blood sugar, in people with diabetes. In addition, a scope of other analytes useful in both a medical and lifestyle perspective can now be realized. The updated system, which has the size of a grain of rice, will be used in our upcoming human pilot studies already approved by German regulatory authorities,” says Joacim Holter, CEO Lifecare
Patent broadens the scope and application of the Sencell technology
“The patent opens the opportunities to expand the use of the Sencell technology.” Says Prof. Andreas Pfützner, Lifecare’s Chief Scientific Officer and one of the patent inventors. “It increases the scope of protection to include measurement of many parameters in the interstitial fluid, including but not limited to lactate, fructose, and calcium and many other biomarkers.”
This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The company’s patented technology also has the potential for use in various biomarkers. Lifecare AS (Ltd.) is listed on EuronextGrowth (LIFE).
Joacim Holter, CEO, Lifecare AS, email@example.com, +47 40 0590 40
This information is considered to be inside information pursuant to theEU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 03 August, 2021 at 15:40 CET.